MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy
Andreas-Claudius Hoffmann(University of Southern California), Arndt Hartmann(Universitätsklinikum Erlangen), Martin Schüler(German Cancer Research Center), Michael Stöckle(Saarland University), Kathleen D. Danenberg(University of Southern California), Simone Bertz(Friedrich-Alexander-Universität Erlangen-Nürnberg), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Peter J. Wild(Goethe University Frankfurt), Peter V. Danenberg(University of Southern California), Christina Leicht(University Hospital Regensburg)
Cited by 137
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
|Nature Methods|2014|2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k